Cardlytics Inc
For the period ended Dec 31, 2024. Filed Mar 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 12, 2025
CDLX$1.82-6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(Amounts in thousands, except par value amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $65,594 | $91,830 |
| Accounts receivable and contract assets, net | 103,252 | 120,622 |
| Other receivables | 3,801 | 5,379 |
| Prepaid expenses and other assets | 5,336 | 6,097 |
| Total current assets | 177,983 | 223,928 |
| Long-term assets: | ||
| Property and equipment, net | 2,596 | 3,323 |
| Right-of-use assets under operating leases, net | 6,341 | 7,310 |
| Intangible assets, net | 11,371 | 35,003 |
| Goodwill | 159,429 | 277,202 |
| Capitalized software development costs, net | 33,341 | 24,643 |
| Other long-term assets, net | 1,650 | 2,735 |
| Total assets | $392,711 | $574,144 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $3,689 | $4,425 |
| Accrued liabilities: | ||
| Accrued compensation | 5,494 | 11,662 |
| Accrued expenses | 7,175 | 9,587 |
| Partner Share liability | 32,479 | 48,867 |
| Consumer Incentive liability | 45,513 | 52,678 |
| Deferred revenue | 2,154 | 2,405 |
| Short-term debt | 45,863 | — |
| Current operating lease liabilities | 2,025 | 2,127 |
| Current contingent consideration | 4,563 | 39,398 |
| Total current liabilities | 148,955 | 171,149 |
| Long-term liabilities: | ||
| Convertible senior notes, net | 167,729 | 227,504 |
| Line of credit | — | 30,000 |
| Long-term deferred revenue | — | 67 |
| Long-term operating lease liabilities | 6,034 | 6,391 |
| Long-term contingent consideration | — | 4,162 |
| Other long-term liabilities | — | 73 |
| Total liabilities | 322,718 | 439,346 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value—100,000 shares authorized and 51,257 and 39,728 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 10 | 9 |
| Additional paid-in capital | 1,366,958 | 1,243,594 |
| Accumulated other comprehensive income | 3,601 | 2,467 |
| Accumulated deficit | (1,300,576) | (1,111,272) |
| Total stockholders’ equity | 69,993 | 134,798 |
| Total liabilities and stockholders’ equity | $392,711 | $574,144 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.